SUBCATEGORY FEED

Novo Nordisk Lowers Growth Outlook Amid Competition | Pfizer's GLP-1 Comeback: A Strategic Move in the Obesity Drug Market | Pfizer Expands GLP-1 Pipeline with Metsera Acquisition | Novo Nordisk Lowers Growth Outlook Amid Competition | Pfizer's GLP-1 Comeback: A Strategic Move in the Obesity Drug Market | Pfizer Expands GLP-1 Pipeline with Metsera Acquisition

Finance / Pharma

Novo Nordisk Lowers Growth Outlook Amid Competition

Danish pharmaceutical giant Novo Nordisk, maker of Ozempic and Wegovy, is facing increased competition and pricing pressure in the weight loss market, leading to a lowered growth outlook for its leading obesity and diabetes treatments. Desp...

Image via CNBC

Nov 05, 2025 08:05 Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Finance / Pharma

Pfizer's GLP-1 Comeback: A Strategic Move in the Obesity Drug Market

Sep 30, 2025 15:02 Pfizer’s Bold GLP‑1 Comeback, Dividend Safe For Now (NYSE:PFE)

Finance / Pharma

Pfizer Expands GLP-1 Pipeline with Metsera Acquisition

Sep 30, 2025 14:31 Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out

Stocks Stock Market Earnings Markets Crypto Cryptocurrency Investing Stock Analysis Company News Economy